Investorideas.com newswire, breaking biotechnology and pharma news

Wednesday, November 28, 2012

Biopharma Stock Trading Alert: Idenix Pharmaceuticals (NASDAQ: IDIX) on the Move: Stock up over 18%

New York, New York - November 28, 2012 (Investorideas.com Newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector research for independent investors issues a trading alert for biopharma stock, Idenix Pharmaceuticals Inc. (NasdaqGM: IDIX), trading at $5.35, up 0.83 or 18.36% as of 3:14PM EST on over 2.1 Million shares. The stock had a day high of $5.38.
Idenix Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with chronic hepatitis C infection.
Investorideas.com Newswire About NASDAQ
http://www.nasdaq.com/
About InvestorIdeas.com:

InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/ investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 14 online stock directories 24/7 - water, renewable energy, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Medical Technology Stock Q&A with Decision Diagnostics (OTCBB: DECN)

New York, New York, Point Roberts, WA - November 28, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research for independent investors issues an exclusive Q&A interview with Mr. Keith Berman , President and CFO of Decision Diagnostics Corp. (OTCBB: DECN). Mr.Berman discusses the market and opportunity for its lead product, GenStrip® Blood Glucose Test Strips.

Q: Investorideas.com
Keith for investors that aren't familiar with your company, can you give a brief outline of your lead product and what differentiates GenStrip® Blood Glucose Test Strips from its competitors?
A: Mr. Keith Berman, President and CFO
Our Shasta Genstrip product is an at-home diagnostic product for the testing of blood glucose. Genstrip is designed specifically to run on the venerable family of Johnson+Johnson's Lifescan family of meters. This family of meters is in use by over 5 million diabetics worldwide.
At home diagnostic testing is a fast growing market, currently used to monitor blood glucose, primarily as a result of modern society lifestyle issues, and is the most important aid in the fight against spread of diabetes. Genstrip is the first product to reach the market in almost a decade as an alternative to brand name diagnostic products. Since its predecessor generic test strips were sold in the late 1990s, the market for at-home testing has grown 20-fold.
Q: Investorideas.com
A report from MarketResearch.com recently noted - Although the blood glucose testing segment of the in vitro diagnostics (IVD) industry is mature, certain segments of the market, such as home testing devices for diabetes management, will exhibit strong growth . Can you give investors insight as to the size of the market and opportunity?
A: Mr. Keith Berman, President and CFO
At home glucose testing is the fastest growth segment of personal health management. The personal diabetes meter has matured to become another must-have, must-need, home appliance. While at-home testing is not a new market, my father for instance tested his glucose levels using at-home urine test strips in the 1970s, the last decade has seen explosive growth in monitoring diagnostic products The market for at-home blood glucose testing reached $1 billion per year for the first time in 2000. By 2017 the market is expected to reach $32 billion worldwide. A rule of thumb is that the U.S. and Canada account for one-half of the market, the rest of the world the other half.
Q: Investorideas.com
According to your SEC filings the Company is underway with the FDA approval process for GenStrip®. Can you give us a brief outline of the history and the process for approval?
A: Mr. Keith Berman, President and CFO
Shasta Genstrip, like all at-home diagnostic products require approval of the U.S. FDA. The process that Genstrip traveled through, called Substantial Equivalency Review ("SE"), was first put in place in the mid-1970s as a way to speed up the regulatory process. Over the last three decades this "speedy" process has morphed into something never envisioned by the U.S. Congress when these laws and regulations were first passed with near unanimous support. Approvals now take in excess of two years. The SE 510k application was filed in early December 2010.
Q: Investorideas.com
If and when the Company does receive FDA approval what is the timeline for distribution into the sales channels? And how would this typically roll out?
A: Mr. Keith Berman, President and CFO
We have had plenty of time to ready ourselves for the ultimate FDA approval of Genstrip. Because of its unique design all of the potential Genstrip customers already make use daily of original manufacturer's platform. Our potential customer base is well known, well studied, and by new product standards, very large.
By law the company could not take orders for Genstrip until there was/is an approval from FDA, but since February 2011 we have been allowed to do some demonstration projects to collect data etc. We used this time to familiarize the market with the upcoming product through the company's normal and historical distribution channels. We secured a supplier contract with Walmart Stores in an incredible 35 days. We have accepted, as a part of our overall responsibilities, working with the Genstrip manufacturer to make product forecasts. We readied the Genstrip Value Proposition. And, it has not hurt that all of the potential consumers of Genstrip have used the predecessor product for, in some cases, almost a decade.
Decision Diagnostics Company website http://www.decisiondiagnostics.com/
DECN SEC quarterly filing
http://biz.yahoo.com/e/120820/decn10-q.html
More info on DECN at Investorideas.com http://www.investorideas.com/CO/DECN/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Disclosure: Investorideas.com has been compensated one hundred fifty thousand shares for news and content publication and distribution for 45 days
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com and Decision Diagnostics

Tuesday, November 27, 2012

Medical Technology Stock Trading Alert: Decision Diagnostics (OTCBB: DECN) Gains 11%

New York, New York, Point Roberts, WA - November 27, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research for independent investors issues a trading alert for medical technology stock, Decision Diagnostics Corp. (OTCBB: DECN) . The stock is trading at $0.15, gining $ 0.02 or 11.11% as of 10:18AM EST on over 100,000 shares.
Investorideas.com Newswire Decision Diagnostics Corp. (OTCBB: DECN) Lead Product; GenStrip ® Blood Glucose Test Strips
Frequent and accurate testing of blood glucose is essential to the treatment of diabetes. Unfortunately, high costs of testing supplies puts regular monitoring out of reach for many diabetics. GenStrip® Blood Glucose Test Strips make blood glucose testing fast, easy, convenient, and more affordable for anyone living with diabetes. This new diagnostic product is compatible with a family of existing meters provided by the platform manufacturer, but priced significantly (50%) lower. GenStrip is in the final stages of FDA approval.
Become an Investor Ideas member today, login to stock directories and investor newsletter In March 2012 and then again September 2012 representatives of the company and Shasta Technologies LLC met face-to-face with the FDA to ask questions and respond to FDA comments and to present its case in an effort to complete the FDA review process. Subsequently Shasta Technologies LLC and the company have received and responded to a short series of follow up questions and comments by FDA.
Decision Diagnostics Company websitehttp://www.decisiondiagnostics.com/
DECN SEC file

http://biz.yahoo.com/e/ 120820/decn10-q.html
More info on DECN at Investorideas.com http://www.investorideas.com/ CO/DECN/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Disclosure: Investorideas.com has been compensated one hundred fifty thousand shares for news and content publication and distribution for 45 days
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Wednesday, November 21, 2012

Medical Technology Stock Decision Diagnostics (OTCBB: DECN) Lead Product Shasta Genstrip Positions for at-home testing of Blood Glucose Market

New York, New York, Point Roberts, WA - November 21, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research for independent investors issues an investor alert for Decision Diagnostics Corp. (OTCBB: DECN) for investors following medical technology stocks . The Company's lead product, Shasta Genstrip, is currently in the FDA approval process for at-home testing of blood glucose, currently estimated at $22.5 Billion Worldwide.

According to MarketResearch.com "There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes, particularly Type 2 diabetes, among adults across the world. As such, the global market for blood glucose testing products is undergoing a significant transition driven by the advent of new analytical technologies and developments in diabetes treatment. Although the blood glucose testing segment of the in vitro diagnostics (IVD) industry is mature, certain segments of the market, such as home testing devices for diabetes management, will exhibit strong growth.”
Source: http://www.marketresearch.com/TriMark-Publications-v2605/Blood-Glucose-Testing-Diabetes-Management-6822260/
Decision Diagnostics Corp. (OTCBB: DECN) GenStrip® Blood Glucose Test Strips
Frequent and accurate testing of blood glucose is essential to the treatment of diabetes. Unfortunately, high costs of testing supplies puts regular monitoring out of reach for many diabetics. GenStrip® Blood Glucose Test Strips make blood glucose testing fast, easy, convenient, and more affordable for anyone living with diabetes. This new diagnostic product is compatible with a family of existing meters provided by the platform manufacturer, but priced significantly (50%) lower. GenStrip is in the final stages of FDA approval.
Become an Investor Ideas member today, login to stock directories and investor newsletter In March 2012 and then again September 2012 representatives of the company and Shasta Technologies LLC met face-to-face with the FDA to ask questions and respond to FDA comments and to present its case in an effort to complete the FDA review process. Subsequently Shasta Technologies LLC and the company have received and responded to a short series of follow up questions and comments by FDA.
Decision Diagnostics Company websitehttp://www.decisiondiagnostics.com/
DECN SEC quarterly file
http://biz.yahoo.com/e/120820/decn10-q.html
More info on DECN at Investorideas.com http://www.investorideas.com/CO/DECN/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Disclosure: Investorideas.com has been compensated one hundred fifty thousand shares for news and content publication and distribution for 45 days
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Monday, November 19, 2012

Medical Diagnostic Stock Alert: Decision Diagnostics (OTCBB: DECN) Aims at home testing of blood glucose market with lead product, Shasta Genstrip

New York, New York, Point Roberts, WA - November 19, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research for independent investors, including Medical Diagnostic stocks, issues an investor snapshot for Decision Diagnostics Corp. (OTCBB: DECN). The Company’s lead product, Shasta Genstrip, is currently in the FDA approval process for at-home testing of blood glucose.

Excerpt from Aug-2012 Quarterly Report
Decision Diagnostics Corp. (OTCBB: DECN) is the parent company of a nationwide prescription and non-prescription diagnostics and home testing products distribution business. The U.S. FDA, in a manner similar to prescription drugs, regulates diagnostic test kits and at-home patient testing products similarly to the regulation of prescription medicine. However, the products we distribute, for the most part, do not require a doctor's prescription for anything other than insurance benefit compliance. Our business model works well in this regulated environment.
We have also continued to ready the company, subject to receipt of an expected FDA 510(k) approval, to introduce a proprietary diagnostic product, the Shasta Genstrip, for at-home testing of blood glucose, an estimated $22.5 billion worldwide market. Shasta Genstrip will compete directly with one of the largest worldwide platform manufacturer for at-home blood glucose testing, a product currently used daily by over 3 million diabetes afflicted Americans. In anticipation of the introduction of Genstrip, currently in the FDA approval process, we have phased out sales of those brand name products that have been a backbone of our current distribution business but will, in the future, would have us compete directly with our Shasta Genstrip product.
Typically, and except for our Shasta Genstrip product, which is an alternative product, we distribute name brand products manufactured primarily by large U.S. and international pharmaceutical companies. The company directs its marketing efforts to ambulatory and semi-ambulatory older Americans afflicted with diabetes and complications caused by diabetes and old age. The company, originally a medical IT company with proprietary IT product lines, acquired its medical products distribution business in late 2004 through a merger with Phoenix, Arizona based CareGeneration, Inc. We have grown the original CareGeneration business through subsequent acquisitions of private businesses and strategic partnerships with larger private pharmacies.
In March 2012 and then again September 2012 representatives of the company and Shasta Technologies LLC met face-to-face with the FDA to ask questions and respond to FDA comments and to present its case in an effort to complete the FDA review process. Subsequently Shasta Technologies LLC and the company have received and responded to a short series of follow up questions and comments by FDA.
Company websitehttp://www.decisiondiagnostics.com/
DECN SEC quarterly file
http://biz.yahoo.com/e/120820/decn10-q.html
More info on DECN at Investorideas.com http://www.investorideas.com/CO/DECN/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Disclosure: Investorideas.com has been compensated one hundred fifty thousand shares for news and content publication and distribution for 45 days
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Friday, November 16, 2012

Decision Diagnostics (OTCBB: DECN) Set to Become Force in at-home testing of blood glucose, estimated $22.5 Billion Worldwide

New York, New York, Point Roberts, WA - November 16, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research for independent investors issues a company snapshot for Decision Diagnostics Corp. (OTCBB: DECN) for investors following the Diagnostic sector. The Company’s lead product, Shasta Genstrip, is currently in the FDA approval process for at-home testing of blood glucose.

Excerpt from Aug-2012 Quarterly Report
Decision Diagnostics Corp. (OTCBB: DECN) is the parent company of a nationwide prescription and non-prescription diagnostics and home testing products distribution business. The U.S. FDA, in a manner similar to prescription drugs, regulates diagnostic test kits and at-home patient testing products similarly to the regulation of prescription medicine. However, the products we distribute, for the most part, do not require a doctor's prescription for anything other than insurance benefit compliance. Our business model works well in this regulated environment.
We have also continued to ready the company, subject to receipt of an expected FDA 510(k) approval, to introduce a proprietary diagnostic product, the Shasta Genstrip, for at-home testing of blood glucose, an estimated $22.5 billion worldwide market. Shasta Genstrip will compete directly with one of the largest worldwide platform manufacturer for at-home blood glucose testing, a product currently used daily by over 3 million diabetes afflicted Americans. In anticipation of the introduction of Genstrip, currently in the FDA approval process, we have phased out sales of those brand name products that have been a backbone of our current distribution business but will, in the future, would have us compete directly with our Shasta Genstrip product.
Typically, and except for our Shasta Genstrip product, which is an alternative product, we distribute name brand products manufactured primarily by large U.S. and international pharmaceutical companies. The company directs its marketing efforts to ambulatory and semi-ambulatory older Americans afflicted with diabetes and complications caused by diabetes and old age. The company, originally a medical IT company with proprietary IT product lines, acquired its medical products distribution business in late 2004 through a merger with Phoenix, Arizona based CareGeneration, Inc. We have grown the original CareGeneration business through subsequent acquisitions of private businesses and strategic partnerships with larger private pharmacies.
In March 2012 and then again September 2012 representatives of the company and Shasta Technologies LLC met face-to-face with the FDA to ask questions and respond to FDA comments and to present its case in an effort to complete the FDA review process. Subsequently Shasta Technologies LLC and the company have received and responded to a short series of follow up questions and comments by FDA.
Company websitehttp://www.decisiondiagnostics.com/
DECN SEC quarterly file
http://biz.yahoo.com/e/120820/decn10-q.html
More info on DECN at Investorideas.com http://www.investorideas.com/CO/DECN/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Disclosure: Investorideas.com has been compensated one hundred fifty thousand shares for news and content publication and distribution for 45 days
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Tuesday, November 13, 2012

Biotech Stock Breaking News: SUNSHINE BIOPHARMA (OTCBB:SBFM) INITIATES IND-ENABLING STUDIES FOR ITS ANTICANCER COMPOUND, Adva-27a

Montreal, Quebec, Canada - November 13, 2012 (Investorideas.com Newswire) Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has initiated the IND-Enabling studies for Adva-27a, the Company’s flagship oncology drug candidate. Adva-27a is a small molecule that has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR) in vitro. The newly synthesized material which the Company took delivery of recently has been used to initiate several IND-Enabling experiments which are currently in progress. Some of these experiments include physical characterization of the molecule as well as various biological activity assays including protein binding, enzyme inhibition, cytotoxicity, in vivo clearance and xenograft studies in mice. The results of the IND-Enabling studies constitute an integral part of an IND Application (Investigational New Drug Application) which the Company must file with the regulatory authorities in the US and Canada as part of the drug development and approval process.

"This is a major milestone in our development of Adva-27a", said Dr. Steve N. Slilaty, Sunshine Biopharma's CEO. "We are very excited to be at this point, the last step before Phase I clinical trials", he added.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Published at the investorideas.com newswire
Sign up for the free investor news and biotech stock alerts
Research biotech stocks at the Investor Ideas Biotech stocks Directory
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure:
Investorideas.com was not compensated for this release but previously was compensated by third party on behalf of SBFM: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894